Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

The UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the NHS because it is too expensive.

Despite that decision, NICE says there’s little doubt that ‘histology independent’ drugs like Vitrakvi (entrectinib) – which treat cancer based on the presence of a genetic mutation rather than its location in the body – have the potential to be ‘game changing’ treatments for cancer.